Total Payments
$54,441
2024 Payments
$156.96
Companies
25
Transactions
74
Medicare Patients
916
Medicare Billing
$152,478
Payment Breakdown by Category
Research$49,451 (90.8%)
Consulting$1,950 (3.6%)
Travel$1,668 (3.1%)
Food & Beverage$1,355 (2.5%)
Education$16.24 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $49,451 | 2 | 90.8% |
| Consulting Fee | $1,950 | 1 | 3.6% |
| Travel and Lodging | $1,668 | 5 | 3.1% |
| Food and Beverage | $1,355 | 65 | 2.5% |
| Education | $16.24 | 1 | 0.0% |
Payments by Type
Research
$49,451
2 transactions
General
$4,990
72 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $49,451 | 2 | $0 (2020) |
| Lilly USA, LLC | $1,950 | 1 | $0 (2021) |
| Ethicon Inc. | $1,713 | 7 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $178.80 | 8 | $0 (2023) |
| United Therapeutics Corporation | $159.39 | 3 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $146.43 | 8 | $0 (2023) |
| Gilead Sciences, Inc. | $127.23 | 6 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $116.95 | 6 | $0 (2024) |
| Allergan Inc. | $116.49 | 7 | $0 (2019) |
| Insmed, Inc. | $90.13 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $156.96 | 8 | AstraZeneca Pharmaceuticals LP ($59.34) |
| 2023 | $175.19 | 9 | Grifols USA, LLC ($43.46) |
| 2022 | $1,857 | 12 | Ethicon Inc. ($1,713) |
| 2021 | $1,950 | 1 | Lilly USA, LLC ($1,950) |
| 2020 | $49,486 | 4 | Eli Lilly and Company ($49,451) |
| 2019 | $222.07 | 13 | Allergan Inc. ($96.89) |
| 2018 | $260.90 | 12 | Janssen Pharmaceuticals, Inc ($110.68) |
| 2017 | $333.37 | 15 | Gilead Sciences Inc ($102.23) |
All Payment Transactions
74 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/19/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $14.68 | General |
| Category: RESPIRATORY | ||||||
| 09/11/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: Rare Disease | ||||||
| 09/06/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO | Food and Beverage | In-kind items and services | $24.51 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/14/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: Rare Disease | ||||||
| 05/22/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Respiratory | ||||||
| 05/21/2024 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 02/27/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $26.52 | General |
| Category: Respiratory | ||||||
| 01/19/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $28.30 | General |
| Category: Inflammation | ||||||
| 10/18/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/13/2023 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/13/2023 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $23.41 | General |
| Category: NEUROLOGY | ||||||
| 08/17/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: RESPIRATORY | ||||||
| 07/26/2023 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/29/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $23.01 | General |
| 05/17/2023 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: Respiratory | ||||||
| 05/11/2023 | Grifols USA, LLC | Xembify (Biological) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: Immunology and Neurology | ||||||
| 01/31/2023 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: Pulmonology | ||||||
| 08/18/2022 | Ethicon Inc. | Monarch Platform (Device) | Travel and Lodging | In-kind items and services | $110.09 | General |
| Category: Endo-Mechanical | ||||||
| 08/17/2022 | Ethicon Inc. | Monarch Platform (Device) | Travel and Lodging | In-kind items and services | $143.11 | General |
| Category: Endo-Mechanical | ||||||
| 08/17/2022 | Ethicon Inc. | Monarch Platform (Device) | Travel and Lodging | In-kind items and services | $110.09 | General |
| Category: Endo-Mechanical | ||||||
| 08/16/2022 | Ethicon Inc. | Monarch Platform (Device) | Travel and Lodging | In-kind items and services | $132.82 | General |
| Category: Endo-Mechanical | ||||||
| 08/16/2022 | Ethicon Inc. | Monarch Platform (Device) | Food and Beverage | In-kind items and services | $26.96 | General |
| Category: Endo-Mechanical | ||||||
| 08/16/2022 | Ethicon Inc. | Monarch Platform (Device) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: Endo-Mechanical | ||||||
| 08/11/2022 | Ethicon Inc. | Monarch Platform (Device) | Travel and Lodging | In-kind items and services | $1,172.20 | General |
| Category: Endo-Mechanical | ||||||
| 06/09/2022 | Teva Pharmaceuticals USA, Inc. | AirDuo Digihaler (Drug) | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH COVID 19 INFECTION | Eli Lilly and Company | $49,451 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 430 | 624 | $184,375 | $61,633 |
| 2022 | 7 | 317 | 375 | $155,980 | $50,287 |
| 2021 | 2 | 74 | 99 | $16,763 | $8,394 |
| 2020 | 3 | 95 | 211 | $144,924 | $32,163 |
Total Patients
916
Total Services
1,309
Medicare Billing
$152,478
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 125 | 239 | $48,267 | $17,489 | 36.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 35 | 79 | $20,115 | $12,752 | 63.4% |
| G0509 | Telehealth consultation, critical care, subsequent, physicians typically spend 50 minutes communicating with the patient and providers via telehealth | Office | 2023 | 47 | 66 | $45,474 | $11,400 | 25.1% |
| G0508 | Telehealth consultation, critical care, initial , physicians typically spend 60 minutes communicating with the patient and providers via telehealth | Office | 2023 | 49 | 49 | $36,750 | $8,885 | 24.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 66 | 66 | $18,246 | $6,520 | 35.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 20 | $5,963 | $2,189 | 36.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 28 | 35 | $4,822 | $1,744 | 36.2% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 21 | 21 | $1,438 | $355.74 | 24.7% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 39 | 49 | $3,300 | $299.04 | 9.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 26 | 63 | $19,544 | $10,918 | 55.9% |
| G0509 | Telehealth consultation, critical care, subsequent, physicians typically spend 50 minutes communicating with the patient and providers via telehealth | Office | 2022 | 35 | 46 | $31,694 | $7,508 | 23.7% |
| G0508 | Telehealth consultation, critical care, initial , physicians typically spend 60 minutes communicating with the patient and providers via telehealth | Office | 2022 | 38 | 38 | $28,500 | $6,912 | 24.3% |
| G0509 | Telehealth consultation, critical care, subsequent, physicians typically spend 50 minutes communicating with the patient and providers via telehealth | Facility | 2022 | 29 | 29 | $19,125 | $4,782 | 25.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 38 | 38 | $12,502 | $4,754 | 38.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 42 | 50 | $12,750 | $4,715 | 37.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 31 | 31 | $11,036 | $4,293 | 38.9% |
| G0508 | Telehealth consultation, critical care, initial , physicians typically spend 60 minutes communicating with the patient and providers via telehealth | Facility | 2022 | 21 | 22 | $14,475 | $3,257 | 22.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 23 | 23 | $4,324 | $2,433 | 56.3% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 34 | 35 | $2,030 | $717.21 | 35.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 37 | 55 | $10,395 | $5,613 | 54.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 37 | 44 | $6,368 | $2,780 | 43.7% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 43 | 109 | $112,161 | $23,472 | 20.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 32 | 61 | $22,021 | $6,049 | 27.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 20 | 41 | $10,742 | $2,642 | 24.6% |
About Dr. Aaliya Burza, M.D
Dr. Aaliya Burza, M.D is a Critical Care Medicine healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/21/2008. The National Provider Identifier (NPI) number assigned to this provider is 1477700425.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aaliya Burza, M.D has received a total of $54,441 in payments from pharmaceutical and medical device companies, with $156.96 received in 2024. These payments were reported across 74 transactions from 25 companies. The most common payment nature is "" ($49,451).
As a Medicare-enrolled provider, Burza has provided services to 916 Medicare beneficiaries, totaling 1,309 services with total Medicare billing of $152,478. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease, Pulmonary Disease
- Location Brooklyn, NY
- Active Since 08/21/2008
- Last Updated 12/07/2022
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1477700425
Products in Payments
- Monarch Platform (Device) $1,713
- XARELTO (Drug) $178.80
- AVYCAZ (Drug) $170.97
- Letairis (Drug) $127.23
- OFEV (Drug) $106.92
- Arikayce (Drug) $90.13
- ORENITRAM (Drug) $71.43
- TEZSPIRE (Biological) $48.14
- FASENRA (Biological) $46.40
- Adempas (Drug) $34.08
- ANDEXXA (Biological) $32.82
- System One (Device) $32.17
- ACTHAR (Biological) $24.75
- INSPIRE (Device) $23.41
- Xembify (Biological) $23.11
- TYVASO (Drug) $20.62
- Prolastin-C Liquid (Biological) $20.35
- TRELEGY ELLIPTA (Drug) $17.91
- BREZTRI (Drug) $17.89
- AirDuo Digihaler (Drug) $17.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Brooklyn
Dr. Joshua Rosenberg, M.d, M.D
Critical Care Medicine — Payments: $893,165
Critical Care Medicine $893,165
Dr. Keerthana Keshava, M.b.b.s, M.B.B.S
Critical Care Medicine — Payments: $23,722
Critical Care Medicine $23,722
Dr. Yizhak Kupfer, Md, MD
Critical Care Medicine — Payments: $22,120
Critical Care Medicine $22,120
Mediha Ibrahim, M.d, M.D
Critical Care Medicine — Payments: $14,961
Critical Care Medicine $14,961
Igor Chernyavskiy, M.d, M.D
Critical Care Medicine — Payments: $7,598
Critical Care Medicine $7,598
Chetana Pendkar, M.b.b.s, M.B.B.S
Critical Care Medicine — Payments: $6,717
Critical Care Medicine $6,717